The data presented here demonstrates that AKR1B10 expression is elevated in ER− and HER2+ breast cancers and that within these breast cancer subtypes, high AKR1B10 expression is associated with an increased incidence of metastatic relapse at secondary sites. Here, ERBB2 is linked to breast cancer.